Seattle, WA -- (SBWire) -- 11/07/2019 --Recombinant protein is a protein that is encoded by a gene named 'recombinant DNA' and has been cloned in a system, which supports expression of gene and translation of messenger RNA. Recombinant proteins are classified on the basis of type namely hormones, growth factor, cytokines, plasma protein factor, recombinant metabolic enzymes, and others. Manufacturers such as Biocon, Ltd., Eli Lilly, and Company, Genentech, Inc., Novo Nordisk Pharmatech A/S, Prospec-Tany Technogene Ltd., Abcam plc, and BPS Bioscience, Inc. offer recombinant proteins for various applications such as drug discovery and development.

Advancements in rDNA technology such as Clustered regularly interspaced short palindromic repeats (CRISPR) technique has complemented recombinant protein production. Furthermore, advancements in associated processes such as protein purification methods, alternative expression technologies, development of alternative cell lines, and enhanced cell culture systems have simplified and optimized the recombinant protein production processes.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1516

Biopharmaceutical organizations are focused on research and development activities in novel biosimilars for life threatening diseases such as cardiovascular diseases, cancer, metabolic disorders such as diabetes, and some rare conditions such as hemophilia. According to Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority was by all biopharmaceutical companies in the U.S.

Furthermore, rare disease medical space holds potential, as there is relatively low competition. This is due to less understanding of the disease progression pathways and entities. Therefore, key players in the market are involved in R&D for development of biologics and subsequently biosimilars in this space. Some of the biosimilars available in the market include Eprex, manufactured by Janssen-Cilag Pty Ltd., which has been successful in treatment of anemia. Demand for biosimilars is increasing significantly, owing to high prices of biologics, in turn leading to high demand for recombinant protein.

The global recombinant protein market was valued at US$ 347.2 million in 2016 and is expected to witness a robust CAGR of 6.2% over the forecast period (2017–2025).

Discovery of innovative technologies in various areas related to or facilitating recombinant protein is expected to drive growth of global recombinant protein market. For instance, recombinant protein processes optimized and simplified due to development of alternative expression technologies such as mammalian cell expression, baculovirus expression, and E.coli expression, development of alternative cell lines, and enhanced cell culture systems. Furthermore, advanced chromatography protein purification methods such as FPLC and HPLC help in providing highly purified clinical grade recombinant proteins. CRISPR technique is a genome editing technique, which is used to target destruction in human cells and can improve recombinant protein production. Moreover, advancements in bioreactor systems have improved the product's output within shorter time. According to National Centre for Biotechnology Information (NCBI), in 2014, about 65.6% of clinical scale manufacturers and 42% of commercial manufacturers adopted single use bioreactor for improvement in their bioprocessing.

For more information, see Download PDF Copy Here @ https://www.coherentmarketinsights.com/insight/request-pdf/1516

However, factors such as complex manufacturing process, high costs, and requirement of high quality of these products (responsible for high costs) are expected to restrain growth of the market over the forecast period.
Some major players operating in the global recombinant protein market include Crown Bioscience, Inc., ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Sigma Aldrich Company Ltd., Novoprotein Scientific, PeproTech, Inc., Feldan Bio, Inc., BioVision, Inc., HumanZyme, Inc., and GenScript Biotech Corporation.